Our findings confirm the results of three previous meta-analyses [19–21, 45] that evaluated the effect of combination therapy with an SGLT2 inhibitor and a GLP-1 RA on cardiovascular and kidney outcomes in individuals with type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.